| 000 | 03399cam a2200349 a 4500 | ||
|---|---|---|---|
| 003 | EG-GiCUC | ||
| 005 | 20250223032603.0 | ||
| 008 | 200924s2020 ua dh f m 000 0 eng d | ||
| 040 |
_aEG-GiCUC _beng _cEG-GiCUC |
||
| 041 | 0 | _aeng | |
| 049 | _aDeposite | ||
| 097 | _aPh.D | ||
| 099 | _aCai01.08.09.Ph.D.2020.Ne.P | ||
| 100 | 0 | _aNesma Mohamed Esmat Aboelnasr | |
| 245 | 1 | 0 |
_aPossible effect of an angiotensin II receptor blocker against hepatic non- enzymatic glycation associated with insulin resistance-induced in rats / _cNesma Mohamed Esmat Abo Elnasr ; Supervised Hanan Elabhar , Sawsan Salah Elden , Salwa Mohamed Nofal |
| 246 | 1 | 5 | _aالتأثير المحتمل لأحد مقيدات مستقبل الانجيوتنسين 2 ضد تكوين التسكر الكبدى غير الانزيمى المصاحب لمقاومة الانسولين المحدث فى الجرذان |
| 260 |
_aCairo : _bNesma Mohamed Esmat Aboelnasr , _c2020 |
||
| 300 |
_a139 P . : _bcharts , facsmilies ; _c25cm |
||
| 502 | _aThesis (Ph.D.) - Cairo University - Faculty of Pharmacy - Department of Pharmacology and Toxicology | ||
| 520 | _aOlmesartan (OLM), an angiotensin receptor blocker, was tested against diabetes/insulin resistance (IR) models associated with renal/cardiovascular complications. Methods: we tested its potential role against diabetes-induced hepatic hitches using an IR/type2 diabetic (IR/D) model induced by high fat/high fructose diet for 7 weeks + a single sub-diabetogenic dose of streptozotocin (35mg/ kg; i.p). IR/D rats were orally treated with OLM (10 mg/kg), pioglitazone (PIO; 5 or 10 mg/kg) or their combinations for 4 consecutive weeks. OLM alone opposed the detrimental effects of IR/D; it significantly improved metabolic parameters, liver function, and abated hepatic oxidative stress, and inflammatory cytokine interleukin-6 (IL-6) and its upstream mediator nuclear factor kappa B. Consequently, OLM turned off the downstream cue p- Jak2/STAT3/SOCS3. Moreover, it suppressed the elevated AGE/RAGE/p-JNK pathway and increased the PPAR-{u0264} /adiponectin cue to signify its anti-inflammatory and anti-oxidant capacity (GSH, MDA). Nevertheless, co-administration of OLM to PIO showed a synergistic improvement in all the aforementioned parameters in a dose dependent manner. Additionally, OLM with PIO 10 provoked a surge in hepatic PPAR-{u0264} and adiponectin (5 and 6 folds) with a sharp decrease of about 85% in the NF-mB/IL-6/p-STAT3/SOCS3 pathway. These effects were confirmed by the histopathological study. In conclusion, OLM and its combination with PIO enhanced insulin sensitivity and guarded against hepatic complications associated with type 2 diabetes probably via modulating various inter-related pathways; namely, metabolic alteration, renin-angiotensin system, inflammatory trajectories, as well as oxidative stress. This study manifests the potential synergistic effects of OLM as an adjuvant therapy to the conventional antidiabetic therapies | ||
| 530 | _aIssued also as CD | ||
| 653 | 4 | _aDiabetes | |
| 653 | 4 | _aInsulin resistance | |
| 653 | 4 | _aOlmesartan | |
| 700 | 0 |
_aHanan Elabhar , _eSupervisor |
|
| 700 | 0 |
_aSalwa Mohamed Nofal , _eSupervisor |
|
| 700 | 0 |
_aSawsan Salah Elden , _eSupervisor |
|
| 856 | _uhttp://172.23.153.220/th.pdf | ||
| 905 |
_aAmira _eCataloger |
||
| 905 |
_aNazla _eRevisor |
||
| 942 |
_2ddc _cTH |
||
| 999 |
_c77905 _d77905 |
||